에스케이바이오팜
Not investment advice · For research purposes only; not a solicitation or an offer of any financial product. Past statistics do not indicate future outcomes. Facts from filings and public sources; not investment advice. No valuation estimate, direction or trading levels are provided.
① Fact table
Values as filed · consolidated / separate basis per year · no interpretation
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | Unit |
|---|---|---|---|---|---|---|
| Revenue | basis unknown | basis unknown | KRW 354.9bn | KRW 547.6bn | KRW 706.7bn | KRW |
| Operating income | basis unknown | basis unknown | -KRW 37.5bn | KRW 96.3bn | KRW 203.9bn | KRW |
| Net income | basis unknown | basis unknown | -KRW 35.4bn | KRW 240.7bn | KRW 267.0bn | KRW |
| Total equity | basis unknown | basis unknown | KRW 283.7bn | KRW 546.3bn | KRW 813.0bn | KRW |
| Total liabilities | basis unknown | basis unknown | KRW 402.2bn | KRW 462.8bn | KRW 372.0bn | KRW |
| 부채비율(자체 계산: 부채총계 ÷ 자본총계 × 100, 자본 0 이하면 비움, 같은 해 같은 기준)· in house | basis unknown | basis unknown | 141.78 | 84.72 | 45.76 | % |
| Statement basis | Unknown | Unknown | Consolidated | Consolidated | Consolidated |
Show raw values
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | Unit |
|---|---|---|---|---|---|---|
| Revenue | — | — | 354,891,555,524 | 547,596,283,214 | 706,740,960,308 | KRW |
| Operating income | — | — | -37,522,197,049 | 96,339,659,521 | 203,938,471,064 | KRW |
| Net income | — | — | -35,379,488,498 | 240,738,037,875 | 266,950,497,803 | KRW |
| Total equity | — | — | 283,686,371,114 | 546,273,129,341 | 813,035,724,864 | KRW |
| Total liabilities | — | — | 402,219,382,621 | 462,826,530,311 | 372,039,049,706 | KRW |
| 부채비율(자체 계산: 부채총계 ÷ 자본총계 × 100, 자본 0 이하면 비움, 같은 해 같은 기준) | — | — | 141.78 | 84.72 | 45.76 | % |
Source: dart_fnltt · Computed in house · card as of 2026-10-13 · Filing date per year: not on the card (see the filing timeline below) · 'in house' marks items computed from the values above
② Profitability breakdown
Arithmetic on the fact table only · same year, same basis · '—' where a value is missing or the denominator is 0 or below · in each panel the bar height maps the span from the most negative to the largest positive value onto the panel height · no interpretation attached
Source: computed in house from the fact table · card as of 2026-10-13
③ My own calculation
A simple residual-income formula. You enter the assumptions; only the base equity is filled in from the filing. The result is computed from your assumptions and is not a figure this site publishes.
V = B₀ + (ROE − r) × B₀ ÷ (1 + r − ω)
Fill in all four boxes to compute. The site fills in nothing but the base equity.
Computed in this browser only; nothing you type is sent or stored.
- Base close 2026-10-13
- 70,700
- 80%
- 68,365.47 ~ 73,412.07
- 90%
- 67,277.60 ~ 74,397.79
- Ledger row
- f8cdff4b…
Source: fsc_stock_price · published 2026-10-14T11:05:08+09:00 · No direction implied
No day scored yet — no basis for a hit rate.
- 2026-09-23Filing title as filed단일판매ㆍ공급계약체결 original ↗Source: dart_disclosure
- 2026-09-17Filing title as filed투자판단관련주요경영사항 original ↗Source: dart_disclosure
- 2026-09-15Filing title as filed최대주주등소유주식변동신고서 original ↗Source: dart_disclosure
- 2026-09-15Filing title as filed임원ㆍ주요주주특정증권등소유상황보고서 original ↗Source: dart_disclosure
- 2026-09-15Filing title as filed임원ㆍ주요주주특정증권등소유상황보고서 original ↗Source: dart_disclosure
- 2026-09-14Filing title as filed단일판매ㆍ공급계약체결 original ↗Source: dart_disclosure
- 2026-09-10Filing title as filed기업설명회(IR)개최(안내공시) original ↗Source: dart_disclosure
- 2026-09-10Filing title as filed투자판단관련주요경영사항 (뇌전증 신약 후보 물질 Opakalim의 미국 FDA 임상 2/3상 Partial Clinical Hold 통보 수령) original ↗Source: dart_disclosure
- 2026-08-31Filing title as filed최대주주등소유주식변동신고서 original ↗Source: dart_disclosure
- 2026-08-31Filing title as filed임원ㆍ주요주주특정증권등소유상황보고서 original ↗Source: dart_disclosure
- 2026-08-31Filing title as filed임원ㆍ주요주주특정증권등소유상황보고서 original ↗Source: dart_disclosure
- 2026-08-27Filing title as filed대규모기업집단현황공시[분기별공시(개별회사용)] original ↗Source: dart_disclosure
- 2026-08-26Filing title as filed기업설명회(IR)개최(안내공시) original ↗Source: dart_disclosure
- 2026-08-26Filing title as filed투자판단관련주요경영사항 (뇌전증 신약 후보 물질 Opakalim 등에 대한 라이선스 인 계약) original ↗Source: dart_disclosure
- 2026-08-26Filing title as filed[첨부추가]주요사항보고서(중요한자산양수도결정(기타)) original ↗Source: dart_disclosure
- 2026-08-18Filing title as filed단일판매ㆍ공급계약체결 original ↗Source: dart_disclosure
- 2026-08-14Filing title as filed반기보고서 (2026.06) original ↗Source: dart_disclosure
- 2026-08-14Filing title as filed지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항 original ↗Source: dart_disclosure
- 2026-08-05Filing title as filed연결재무제표기준영업(잠정)실적(공정공시) original ↗Source: dart_disclosure
- 2026-08-03Filing title as filed기업설명회(IR)개최(안내공시) original ↗Source: dart_disclosure
| Layer | Badge | n | Note |
|---|---|---|---|
| range | unknown | 0 | 80%·90% 범위의 전향 적중 기록(목표일 개장 전 박제 → 종가 공표 뒤 채점) |
| fair_value | 제공 안 함 | 0 | 판별력 미확인 — 싣지 않음 |
| direction | 제공 안 함 | 0 | 판별력 미확인 — 싣지 않음 |
| trade_levels | 제공 안 함 | 0 | 판별력 미확인 — 싣지 않음 |
| Valuation estimate | not provided | — | Not published: no demonstrated discriminative power |
| Direction (up or down) | not provided | — | Not published: no demonstrated discriminative power |
| Trading levels | not provided | — | Not published: no demonstrated discriminative power |
- 재무 — 2021 재무 기준(연결·별도) 미상 — 그 해 값 싣지 않음
- 재무 — 2022 재무 기준(연결·별도) 미상 — 그 해 값 싣지 않음
Why this?
Checking…